Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology

Guth S , Theune U , Aberle J , Galach A , Bamberger CM . 2009. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest, 39:699–706.

Mazzaferri EL . 1993. Management of a solitary thyroid nodule. N Engl J Med, 328:553–559.

Yassa L , Cibas ES , Benson CB , Frates MC , Doubilet PM , Gawande AA , Moore FD Jr , Kim BW , Nose V , Marqusee E , Larsen PR , Alexander EK . 2007. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer, 111:508–516.

Bongiovanni M , Spitale A , Faquin WC , Mazzucchelli L , Baloch ZW . 2012. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol, 56:333–339.

Haugen BR , Alexander EK , Bible KC , Doherty GM , Mandel SJ , Nikiforov YE , Pacini F , Randolph GW , Sawka AM , Schlumberger M , Schuff KG , Sherman SI , Sosa JA , Steward DL , Tuttle RM , Wartofsky L . 2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid nodules and differentiated thyroid cancer. Thyroid, 26:1–133.

Alexander EK , Schorr M , Klopper J , Kim C , Sipos J , Nabhan F , Parker C , Steward DL , Mandel SJ , Haugen BR . 2014. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab, 99:119–125.

Angell TE , Heller HT , Cibas E , Barletta J , Kim MI , Krane JF , Marqusee E . 2019. An independent comparison of the Afirma genomic sequencing classifier (GSC) and gene expression classifier (GEC) for cytologically indeterminate thyroid nodules. Thyroid, 29:650–656.

Endo M , Nabhan F , Porter K , Roll K , Shirley LA , Azaryan I , Tonkovich D , Perlick J , Ryan LE , Khawaja R , Meng S , Phay JE , Ringel MD , Sipos JA . 2019. Afirma Gene Sequencing Classifier compared with gene expression classifier in indeterminate thyroid nodules. Thyroid, 29:1115–1124.

Harrell RM , Eyerly-Webb SA , Golding AC , Edwards CM , Bimston DN . 2018. Statistical comparison of Afirma Gsc and Afirma Gec outcomes in a community endocrine surgical practice: Early findings. Endocr Pract, 25:161–164.

San Martin VT , Lawrence L , Bena J , Madhun NZ , Berber E , Elsheikh TM , Nasr CE . 2019 Real world comparison of Afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 105:pii: dgz099.

Livhits MJ , Kuo EJ , Leung AM , Rao J , Levin M , Douek ML , Beckett KR , Zanocco KA , Cheung DS , Gofnung YA , Smooke-Praw S , Yeh MW . 2018. Gene Expression Classifier vs targeted next-generation sequencing in the management of indeterminate thyroid nodules. J Clin Endocrinol Metab, 103:2261–2268.

Haddad LBRI, Busaidy NL, Callender G, Dickson P, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Roth M, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong R 2019 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Thyroid Carcinoma NCCN Evidence Blocks Version 1.

Grani G , Lamartina L , Durante C , Filetti S , Cooper DS . 2018. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol, 6:500–514.

Ganly I , McFadden DG . 2019. Short Review: genomic alterations in Hurthle cell carcinoma. Thyroid, 29:471–479.

Ganly I , Makarov V , Deraje S , Dong Y , Reznik E , Seshan V , Nanjangud G , Eng S , Bose P , Kuo F , Morris LGT , Landa I , Carrillo Albornoz PB , Riaz N , Nikiforov YE , Patel K , Umbricht C , Zeiger M , Kebebew E , Sherman E , Ghossein R , Fagin JA , Chan TA . 2018. Integrated genomic analysis of Hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell, 34:256–270 e255.

Gopal RK , Kubler K , Calvo SE , Polak P , Livitz D , Rosebrock D , Sadow PM , Campbell B , Donovan SE , Amin S , Gigliotti BJ , Grabarek Z , Hess JM , Stewart C , Braunstein LZ , Arndt PF , Mordecai S , Shih AR , Chaves F , Zhan T , Lubitz CC , Kim J , Iafrate AJ , Wirth L , Parangi S , Leshchiner I , Daniels GH , Mootha VK , Dias-Santagata D , Getz G , McFadden DG . 2018. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hurthle cell carcinoma. Cancer Cell, 34:242–255 e245.

Schatz-Siemers N , Brandler TC , Oweity T , Sun W , Hernandez A , Levine P . 2019. Hurthle cell lesions on thyroid fine needle aspiration cytology: molecular and histologic correlation. Diagn Cytopathol, 47:977–985.

Steward DL , Kloos RT . 2014. Clinical diagnostic gene expression thyroid testing. Otolaryngol Clin North Am, 47:573–593.

Brauner E , Holmes BJ , Krane JF , Nishino M , Zurakowski D , Hennessey JV , Faquin WC , Parangi S . 2015. Performance of the Afirma gene expression classifier in Hurthle cell thyroid nodules differs from other indeterminate thyroid nodules. Thyroid, 25:789–796.

Hao Y , Duh QY , Kloos RT , Babiarz J , Harrell RM , Traweek ST , Kim SY , Fedorowicz G , Walsh PS , Sadow PM , Huang J , Kennedy GC . 2019. Identification of Hurthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms. BMC Syst Biol, 13:27.

Wei S , Veloski C , Sharda P , Ehya H . 2019. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: an institutional experience. Cancer Cytopathol, 127:720–724.

Steward DL , Carty SE , Sippel RS , Yang SP , Sosa JA , Sipos JA , Figge JJ , Mandel S , Haugen BR , Burman KD , Baloch ZW , Lloyd RV , Seethala RR , Gooding WE , Chiosea SI , Gomes-Lima C , Ferris RL , Folek JM , Khawaja RA , Kundra P , Loh KS , Marshall CB , Mayson S , McCoy KL , Nga ME , Ngiam KY , Nikiforova MN , Poehls JL , Ringel MD , Yang H , Yip L , Nikiforov YE . 2018. Performance of a Multigene Genomic Classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol, 5:204–212.

Ohori NP , Landau MS , Carty SE , Yip L , LeBeau SO , Manroa P , Seethala RR , Schoedel KE , Nikiforova MN , Nikiforov YE . 2019. Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathol, 127:161–168.